About Us
Equillium is a clinical-stage biopharmaceutical company developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Our lead asset, itolizumab, targets the CD6-ALCAM signaling pathway, which plays a central role in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab has potential to be a best-in-class disease-modifying therapeutic and is currently being evaluated in clinical trials in multiple indications, including a planned pivotal study in acute graft-versus-host-disease (aGVHD), an ongoing Phase 1b study in lupus/lupus nephritis and an ongoing Phase 1b study in uncontrolled asthma.
